Drug Profile

VAX 31

Alternative Names: 31-valent PCV; 31-Valent Pneumococcal Conjugate Vaccine - Vaxcyte; Pneumonococcal conjugate vaccine - Vaxcyte; VAX-31; VAX-XP

Latest Information Update: 09 Oct 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vaxcyte
Class Conjugate vaccines; Pneumococcal vaccines; Protein vaccines; Synthetic vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

05 Oct 2026 Vaxcyte plans to submit the Biologics License Application (BLA) in first half of 2028
05 Oct 2026 Immunogenicity and adverse events data from a phase III OPUS-1 trial in Pneumococcal-infections released by Vaxcyte
07 May 2026 Vaxcyte completes enrolment in its phase III OPUS-3 trial for Pneumococcal infections (Prevention, In adults, In the elderly) in USA (IM, injection) (NCT07425392)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com